Nudge

Nudge develops non‑invasive focused‑ultrasound systems that both image and stimulate deep brain circuits. Its platform is intended for treating conditions with high unmet need, including anxiety, OCD, depression, addiction and chronic pain, and the company envisions a future headphone‑like device for healthy users to boost mood and cognition. The company was founded in 2024 in San Francisco by Fred Ehrsam, Jeremy Barenholtz and Quintin Frerichs. It is a privately held biotechnology firm with a headcount of around 37 employees, all based at its San Francisco headquarters. Nudge’s engineering work involves hardware design, ultrasound phased‑array technology, MRI‑verified targeting, and embedded firmware for precise brain modulation. For fresh graduates, the founders highlight the opportunity to work on technically challenging problems in a mission‑driven environment, with direct access to the leadership team and a focus on building a regulated medical‑device product. No specific graduate program or mentorship details are provided in the sources, but employees are described as exceptional researchers and engineers attracted to the meaningful mission.